Dapagliflozin - do we need it registered for type 2 diabetes? by Doggrell, Sheila & Tuli, Rinku
This is the author’s version of a work that was submitted/accepted for pub-
lication in the following source:
Doggrell, Sheila A. & Tuli, Rinku
(2014)
Dapagliflozin – do we need it registered for type 2 diabetes?
Expert Opinion on Pharmacotherapy, 15(11), pp. 1631-1635.
This file was downloaded from: http://eprints.qut.edu.au/78692/
c© Copyright 2014 Informa UK, Ltd.
Notice: Changes introduced as a result of publishing processes such as
copy-editing and formatting may not be reflected in this document. For a
definitive version of this work, please refer to the published source:
http://doi.org/10.1517/14656566.2014.930438
1 
 
KEY PAPER EVALUATION  
 
Dapagliflozin – do we need it registered for type 2 diabetes? 
 
Evaluation of Jabbour SA, Hardy E, Sugg J, Parikh S. Dapagliflozin is effective as add-on 
therapy to sitagliptin with or without metformin: a 24-week, multicentre, randomized, double-
blind, placebo-controlled study. Diabetes Care 2014;37:740-50. 
 
 
Abstract 
 
Introduction: Inhibitors of the sodium glucose co-transporter 2 (SGLT2) promote the 
excretion of glucose to reduce HbA1c levels.  Canagliflozin was the first SGLT2 inhibitor to 
be approved by the US Food and Drug Administration (FDA) for use in the treatment of type 
2 diabetes, and recently dapagliflozin has also been approved. 
 
Areas covered: We evaluated a recent Phase III clinical trial with dapagliflozin. 
 
Expert Opinion: Dapagliflozin was studied as add-on therapy to sitagliptin with or without 
metformin, and shown to lower HbA1c levels and body weight.  The incidence of 
hypoglycaemia was low with dapagliflozin, but it did increase the incidence of urogenital 
infections.  As no clear benefits have been identified for dapagliflozin over canagliflozin, 
which was the first gliflozin registered by the FDA, we do not fully understand why it was 
necessary to register dapagliflozin.  Given that there are no completed 
cardiovascular/clinical outcome studies with dapagliflozin, and therefore no evidence of 
beneficial effect, it also seems premature to be using it extensively or considering it as an 
alternative to the clinically proven metformin. 
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1. Introduction 
According to the World Health Organisation, 347 million people worldwide have diabetes 
and, of this diabetes, 90% is type 2.  Over 3 million people die each year from diabetes, and 
50% of subjects with diabetes die of cardiovascular disease (primarily heart disease and 
stroke). Subjects with prolonged diabetes are more likely to have neuropathy, diabetic 
retinopathy, and kidney failure than their non-diabetic peers [1].   
This mortality and morbidity occurs despite having a range of medicines available to treat 
type 2 diabetes including metformin, sulfonylureas, thiazolidinediones, incretins, and 
injectable insulin.  This suggests that new medicines are needed to be used alone or in 
combination with the presently available agents to reduce the effects of diabetes. 
Some recent physiological discoveries have opened up a new paradigm in the treatment of 
diabetes.  The sodium-glucose co-transporters (SGLTs) control the transport of glucose 
across the intestinal epithelium and proximal kidney tubules (reviewed in [2]).  SGLT2 in the 
kidney accounts for 90% of the reabsorption of glucose [2].  Inhibition of SGLT2 causes 
glucosuria, and ultimately a reduction in HbA1c levels, which may be beneficial in the 
treatment of type 2 diabetes [2].  Examples of SGLT2 inhibitors are canagliflozin and 
dapagliflozin, and both have been approved by the US Food and Drug Agency (FDA) for 
treatment of type 2 diabetes.  Canagliflozin was approved in March 2013 [3], and recently, 
dapagliflozin (Farxiga) has been approved (Jan 8th, 2014 [4]).  This evaluation is of a trial of 
dapagliflozin as add-on treatment to sitagliptin with or without metformin in subjects with type 
2 diabetes, and confirms dapagliflozin decreases HbA1c levels. 
2. Dapagliflozin as add-on therapy to sitagliptin with or without metformin 
2.1 Methods and results 
The methods and results of the multicentre, randomized, double-blind, placebo-controlled, 
parallel-group, Phase III trial of dapagliflozin as add-on therapy to sitagliptin, with or without 
metformin [5], are combined and précised in this section.  The parallel groups were with or 
without metformin immediate release (≥ 1500 mg/day) bid with meals.   
Subjects with poor kidney function or high blood pressure were excluded.  The 447 subjects 
enrolled had a mean age of ~ 55 years, there were slightly more males than females, and 
those enrolled were predominantly White (~74%).  As sitagliptin monotherapy is restricted in 
European countries, the parallel groups were not matched for body weight.  All subjects with 
type 2 diabetes were initially stabilised over 10 weeks on sitagliptin 100 mg/day, and then 
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subsequently randomised to dapagliflozin 10 mg or placebo for 24 weeks with a further 24 
weeks extension. 
The primary efficacy end point was change in HbA1c from baseline at 24 weeks.  In the 221 
subjects taking sitagliptin only (no metformin), baseline HbA1c was 8.0%, and this was 
reduced by 0.5% by dapagliflozin, whereas the placebo group gained 0.1%.  In the 226 
subjects taking sitagliptin and metformin, the baseline HbA1c was 7.9%, and this was 
reduced by 0.4% with dapagliflozin, with no change in the placebo group.  These reductions 
in HbA1c with dapagliflozin were maintained after 48 weeks. 
One of the secondary end points was change in body weight.  In subjects taking sitagliptin 
only, the baseline body weight was ~ 86 kg, and this decreased by 1.9 kg in the dapagliflozin 
group, compared to 0.1 kg in the placebo group.  In the subjects taking sitagliptin and 
metformin, the baseline body weight was higher at 94 kg, probably because more of this 
population were White (88%) than in the population not taking metformin (59%).  Body 
weight was reduced by 2.4 kg in the dapagliflozin group, compared to no change in the 
control group.  These reductions in body weight with dapagliflozin were maintained after 48 
weeks.  Dapagliflozin caused small increases in total cholesterol (3.6%), LDL cholesterol 
(3.6%) and HDL cholesterol (4.6%), and a small decrease in triglycerides (1.9%) at 24 and 
48 weeks.   
The incidence of many adverse effects (hypoglycemia, 
hypotension/dehydration/hypovolemia, kidney infection), was similar in the dapagliflozin and 
placebo groups.  However, there was more renal impairment with dapagliflozin (3.6%) than 
in the placebo group (1.8%) due to a more decreased creatinine clearance with 
dapagliflozin. 
Vulvovaginitis/balanitis infection (signs, symptoms and events suggestive) was greater in the 
dapagliflozin group (24 weeks, 8.4%; 48 weeks, 9.8%) than in the placebo group (0.4% at 24 
and 48 weeks).  Most of subjects (75%) who had these genital infections were women, with 
one women discontinuing dapagliflozin due to vulvovaginal mycotic infection.  Urinary tract 
infections were diagnosed to a greater extent with dapagliflozin (24 weeks, 3.6%; 48 weeks, 
5.8%) than placebo (1.3% and 3.5%).  One event of prostate neoplasm and one of thyroid 
neoplasm was reported with dapagliflozin. 
2.2 Discussion 
In their discussion, the authors point out that this is the first published study evaluating triple 
oral combination therapy that includes dapagliflozin, and demonstrates that dapagliflozin 
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add-on reduces HbA1c and body weight [5]. The authors consider the small changes in 
lipids with dapagliflozin to have no clinical significance [5].  The authors do not give 
importance to the increased renal impairment in this study with dapagliflozin, as previous 
studies with dapagliflozin have not demonstrated this [5]. 
3. Expert opinion 
3.1 Urogenital infections with gliflozins 
The increased glucose excretion with the SGLT2 inhibitors leads to increased urogenital 
infections with the gliflozins, in subjects with type 2 diabetes taking these inhibitors, and 
these are more common in women than men.  Thus, a study combining 4545 subjects 
enrolled in Phase IIb/III studies showed a greater percentage of women (1.5%, 5.8%, 8.4% 
and 6.9%) were diagnosed with genital infections than men (0.3%, 2.4%, 2.8% and 2.7%) in 
all the placebo, dapagliflozin 2.5 mg, 5 mg and 10 mg groups, respectively [6].  Additionally, 
recurrent infections occurred frequently in the dapagliflozin group (18.1%) rather than the 
placebo group (8.3%) [6].  Similar findings were observed with respect to urinary tract 
infections, which were more common in women (6.6%, 5.8%, 9.6% and 7.7%) than men 
(1.0%, 1.4%, 1.6% and 0.8%) in the placebo, dapagliflozin 2.5 mg, 5 mg and 10 mg groups, 
respectively [7].  
Canagliflozin is another SGLT2 inhibitor used in type 2 diabetes mellitus which has shown to 
cause urogenital infections.  Similar to dapagliflozin, the occurrence of incidence was higher 
in females than in males with canagliflozin [8].  As more urogenital adverse effects with the 
gliflozins (SGLT2 inhibitors) appear in women than men, the gliflozins may be preferred for 
use by men over women.  
3.2 Was the dapagliflozin add-on therapy to sitagliptin with or without 
metformin the most suitable trial? 
It seems to us that the rationale for the add-on trial, discussed in this evaluation, is not fully 
justified, and the reasons for this are discussed below.  
3.2.1 Why would you use dapagliflozin prior to metformin? 
In most countries, metformin is the first medication introduced for the treatment of type 2 
diabetes.  However, in the add-on study with dapagliflozin, all the 447 subjects with type 2 
diabetes are taking sitagliptin, but only some of them (226) are taking metformin, and the 
reason why the other 221 subjects are not taking metformin is not given [5].  For metformin, 
improved cardiovascular outcomes were shown in the UK Prospective Diabetes Study 
(UKPDS) 34 [9].  Clinical outcome studies with dapagliflozin have not been undertaken to 
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date.  Thus, it would seem preferential to us, to use the clinically proven metformin, prior to 
adding on dapagliflozin, and that dapagliflozin should only be considered in subjects with 
type 2 diabetes who are unable to take or tolerate metformin.   
3.2.2 Is sitagliptin generally accepted as add-on therapy to metformin? 
When glycaemic control cannot be achieved with metformin alone, in subjects with type 2 
diabetes, add-on oral treatment with the sulfonylureas is the classical treatment, but other 
add-on treatments have also been considered e.g. insulin. Thus, before considering whether 
dapagliflozin is an appropriate add-on therapy to sitagliptin and metformin, it seems to us, 
that it is necessary to consider whether sitagliptin is an appropriate/best add-on therapy, 
when diabetes cannot be controlled with metformin alone.   
In a study comparing sitagliptin with the sulfonylurea glimepiride in subjects with type 2 
diabetes inadequately controlled with metformin, HbA1c levels were lowered by 0.47% with 
sitagliptin and 0.54% with glimepiride [10].  There was less hypoglycemia with sitagliptin than 
glimepiride, and a weight loss with sitagliptin versus a weight loss with glimepiride [10].  As 
no clinical outcomes have been published from this comparison, we cannot be sure that 
sitagliptin is superior to glimepiride as add-on therapy to metformin. However, the results 
from this comparison do suggest considering sitagliptin as an appropriate option for add-on 
therapy, compared to glimepiride, in subjects with type 2 diabetes not controlled with 
metformin. However, this does not establish sitagliptin as the best add-on therapy when type 
2 diabetes is not controlled by metformin alone, as other add-ons may be better than 
sitagliptin or glimepiride e.g. insulin. 
Another approach to glycaemic control, when it cannot be controlled with metformin alone, is 
to add-on insulin.  Thus, it is necessary to compare sitagliptin with insulin as add on 
treatment, before accepting sitagliptin as the best add-on treatment to metformin.  This was 
not the finding of the EASIE (Evaluation of insulin glargine versus Sitagliptin in Insulin-naïve 
patients) trial [11].  EASIE compared insulin glargine and sitagliptin in 515 subjects with type 
2 diabetes, uncontrolled with metformin, and a baseline HbA1c of 8.5% [11].  HbA1c was 
reduced by 1.7% by insulin glargine, compared to 1.1% with sitagliptin [11].  The incidence 
of severe hypoglycaemia was low, and occurred in three subjects on insulin glargine, and 
one on sitagliptin [11].  The authors of EASIE suggest that the achievement of better 
glycaemic control with insulin glargine than sitagliptin may lead to better outcomes [11], 
although this has not been tested.  Without good evidence that sitagliptin is a good add-on 
therapy to metformin, it seems to us, that it may be premature to be considering dapagliflozin 
as add-on therapy to sitagliptin and metformin in subjects with type 2 diabetes. 
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3.2.3 Dapagliflozin as add-on therapy to sitagliptin and metformin 
In the rationale for the study using dapagliflozin as add-on therapy to sitagliptin and 
metformin, the authors state that when two oral anti-diabetic medicines are not enough to 
control HbA1c levels, insulin is usually added [5].  However, they consider a third oral 
medication e.g. dapagliflozin, should be considered before introducing insulin [5].  As 
dapagliflozin has a different mechanism of action, it is not surprising that it reduces HbA1c in 
the presence of metformin and sitagliptin [5], but the additional effect was relatively modest, 
~0.5%.  A much more important question is whether the combination of metformin, sitagliptin 
and dapagliflozin is superior to metformin, sitagliptin and insulin in reducing HbA1c levels 
and clinical outcomes in subjects with type 2 diabetes, and this was not tested in the add-on 
study, and should be tested in the future. 
3.3 Dapagliflozin does not reduce HbA1c in subjects with impaired kidney 
function 
In both of the studies evaluated here, subjects with type 2 diabetes and impaired kidney 
function were excluded.  Thus, neither study considers whether dapagliflozin can be used in 
subjects with impaired kidney function.  This is an important consideration, as kidney 
disease is very common in subjects with long standing type 2 diabetes.  In subjects with type 
2 diabetes, improvements with SGLT2 inhibitors, such as dapagliflozin, will depend on the 
kidney’s ability to filter glucose.  Recently, it has been shown that human plasma levels of 
dapagliflozin are incrementally increased with declining renal function, and the ability of 
dapagliflozin to increase the renal clearance of glucose is also reduced in renal impairment 
in subjects with type 2 diabetes [12].  Dapagliflozin has also been tested in 252 subjects with 
inadequately controlled type 2 diabetes, and moderate renal impairment, and shown not to 
significantly decrease HbA1c, compared to placebo [13].  Thus, dapagliflozin may not be 
suitable for long-term treatment in subjects with type 2 diabetes as it progresses and kidney 
impairment develops, and this requires testing. 
3.4 Clinical outcome studies 
In their submission to the FDA about dapagliflozin, Bristol Myers Squibb included a meta-
analysis of cardiovascular events in their clinical programme, in which only 37% of subjects 
had a history of cardiovascular disease (excluding hypertension) [14].  In this group, the 
cardiovascular events (cardiovascular death, stroke, myocardial infarction, hospitalization of 
unstable angina) were low; 1.99% in the comparator group, compared to 1.64% per subject 
year in the dapagliflozin [14]. 
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In our opinion, one of the major limitations to the studies to date with dapagliflozin is that no 
clinically beneficial outcomes (e.g. cardiovascular mortality or morbidity) have been 
undertaken in subjects at high cardiovascular risk.  In approving dapagliflozin for use in the 
treatment of type 2 diabetes, the FDA asked for 6 post-marketing trials with dapagliflozin 
[14].  Only one of these is to investigate any beneficial effects of dapagliflozin, and this is a 
cardiovascular outcomes trial to evaluate the cardiovascular risk of dapagliflozin in subjects 
with high baseline risk of cardiovascular disease [15].  This multicenter trial to evaluate the 
effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58) is a 
Phase III trial recruiting high cardiovascular risk subjects with type 2 diabetes [15].  In this 
trial, dapagliflozin or placebo will be added to the subjects’ current anti-diabetes medicines, 
and the primary outcome measure is the composite of cardiovascular death, myocardial 
infarction or ischemic stroke in subjects with type 2 diabetes [15]. DECLARE-TIMI58 is due 
to be completed in April 2019 [15].  This suggests that dapagliflozin will be available for use 
for 5 years before its cardiovascular efficacy and safety is established.  This seems 
inappropriate to us, and we would prefer anti-diabetic medicines to have established benefits 
on cardiovascular outcomes before approval from the FDA for wide use.  The obvious 
precedent for this is rosiglitazone, which effectively lowers HbA1c, and was approved by the 
FDA, but has no benefit or may increase cardiovascular outcomes [16].    
3.5 Do we need dapagliflozin registered for type 2 diabetes? 
At the present time, several countries have two gliflozins approved for use.  In the USA, 
canagliflozin was approved prior to dapagliflozin.  In Europe and Australia, dapagliflozin was 
approved prior to canagliflozin.  To our knowledge, there are no major differences between 
the pharmacology, efficacy and most of the adverse effects with these gliflozins.  Pooled 
evidence suggests that there is not an increased incidence of bladder or breast cancers with 
canagliflozin, but this matter is unresolved for dapagliflozin.  Thus, nine cases of bladder 
cancer and nine cases of breast cancer have occurred in 5000 subject-years of dapagliflozin 
use, and although this pooling does not have enough power to give significance, it does 
raise safety concerns about dapagliflozin [17].  No cases of bladder or breast cancer were 
observed in the relative small and short term of the studies we evaluated.   
Given that there is no present clinical outcome evidence (discussed in previous section) and 
unresolved safety issues for dapagliflozin, we are not sure why dapagliflozin has been 
approved by the FDA.  It seems to us, that drugs should be required to show significant 
differences to those already approved for use (for the FDA, this would be canagliflozin), that 
are beneficial in some subjects with type 2 diabetes, prior to approval. 
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